Framaceutical nanoparticulated composition of an anchangist of the taquikinine receiver.

A nanoparticulate composition comprising the compound 2- (R) - (1- (R) - (3,5-bis (trifluoromethyl) phenyl) ethoxy) -3- (S) - (4-fluoro) phenyl-4- ( 3- (5-oxo-1H, 4H-1,2,4-triazolo) methylmorpholine, or a pharmaceutically acceptable salt thereof, the compound having adsorbed on the surface thereof at least one surface stabilizer in an amount sufficient to maintain an effective average particle size of less than about 1000 nm.